Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | CA7 | P43166 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | MGLL | Q99685 | 1/20 | 0.62 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086635 | 0.88 | RXFP1 (0.81) | RXFP1KDM4ELMNAKMT2ACA12 | |
| SCHEMBL4040436 | 0.88 | RXFP1 (0.85) | RXFP1KDM4ELMNAKMT2ACA12 | |
| SCHEMBL16207564 | 0.87 | RXFP1 (0.74) | RXFP1KDM4ELMNAKMT2ACA12 | |
| SCHEMBL530767 | 0.87 | RXFP1 (0.79) | RXFP1KDM4ELMNAKMT2ACA12 | |
| SCHEMBL3093675 | 0.87 | RXFP1 (0.79) | RXFP1KDM4ELMNAKMT2ACA12 | |
| SCHEMBL15271998 | 0.87 | RXFP1 (0.74) | RXFP1KDM4ELMNAKMT2ACA12 | |
| SCHEMBL15272028 | 0.87 | RXFP1 (0.74) | RXFP1KDM4ELMNAKMT2ACA12 | |
| SCHEMBL520435 | 0.87 | KDM4E (1.00) | RXFP1KDM4ELMNAKMT2ACA12 | |
| SCHEMBL30568796 | 0.87 | KDM4E (1.00) | RXFP1KDM4ELMNAKMT2ACA12 | |
| SCHEMBL3093683 | 0.85 | RXFP1 (0.77) | RXFP1KDM4ELMNAKMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9597333-B2 | Benzazepine dicarboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9597333-B2 | Benzazepine dicarboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9475775-B2 | Benzazepine dicarboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475775-B2 | Benzazepine dicarboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-7935819-B2 | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-05-03 | — | — | US | disclosed |
| US-7935819-B2 | Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-05-03 | — | — | US | disclosed |
| US-20090082379-A1 | Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-03-26 | — | — | US | disclosed |
| US-20090082379-A1 | Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-03-26 | — | — | US | disclosed |
| EP-1979339-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007083017-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007083017-A2 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | WO | disclosed |
| EP-0596406-B1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-12-16 | — | — | EP | disclosed |
| US-5750699-A | HALOGENATING OF CORRESPONDING COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5574042-A | ANTAGONIST FOR BRADYKININS AS ANTIALLERGENS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, SHOCK OR PAIN | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 1996-11-12 | — | — | US | disclosed |
| EP-0596406-A1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082379-A1 | Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | PRKAR2B, CDK1, PRKX | RXFP1 714/4885KDM4E 1711/4885LMNA 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.